<DOC>
	<DOC>NCT00510068</DOC>
	<brief_summary>The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.</brief_summary>
	<brief_title>Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criteria: 1. Patients must have advanced (unresectable or metastatic) biopsyproven pancreatic NET 2. Measurable disease by radiologic assessment 3. Adequate blood work 4. Performance Status 02 : Ability to be out of bed most of the time 5. Adult male or female patients â‰¥ 18 years of age 6. Women of childbearing potential must have a negative serum pregnancy test 7. Written informed consent from patients must be obtained in accordance to local guidelines Exclusion criteria: 1. Patients with severe kind of (poorly differentiated neuroendocrine carcinoma, highgrade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma) cancer are not eligible 2. Other chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to starting this trial 3. Hepatic artery procedure called embolization within the last 6 months (1 month if there are other sites of measurable disease), or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of enrollment 4. Prior therapy with the same kind of medication (mTOR inhibitors: sirolimus, temsirolimus, everolimus). 5. Uncontrolled diabetes mellitus Patients who have any severe and/or uncontrolled medical conditions such as: 6. Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent 7. Patients with a known history of HIV seropositivity 8. No other prior or concurrent cancer at the time enrolling to this trial Other protocol defined inclusion/ exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase III</keyword>
	<keyword>Advanced Neuroendocrine Tumor in adults</keyword>
	<keyword>RAD001</keyword>
	<keyword>NET</keyword>
	<keyword>everolimus</keyword>
	<keyword>mTOr</keyword>
	<keyword>islet cell</keyword>
	<keyword>neuroendocrine</keyword>
</DOC>